Revista Cubana de Investigaciones Biomédicas
On-line version ISSN 1561-3011
RAMIREZ ALBAJES, Victoria et al. Seguridad e inmunogenicidad de la vacuna cubana heberbiovac hb en poblaciones de América, Europa, África y Asia. Rev Cubana Invest Bioméd [online]. 2000, vol.19, n.1, pp. 28-33. ISSN 1561-3011.
Reactogenecity and immunogenicity of the Cuban anti-HBV vaccine called Herberbiovac HB were evaluated in 2 942 adults and 804 children from a number of countries in 3 continents by using 3 doses of this vaccine with different innoculation schedules and routes of administration. Only pain and local induration were found in 15 to 25% of the vaccinated people. Seroprotection was as follows: 98% in children and 82% in adults , with only two doses of vaccination 60 days after the starting of the schedule; 92% and 100% respectively 75 days after the completion of the vaccination program; over 96% in adults after one year when the IM administration was used. After 2 years of finishing the vaccination, seroprotection reached 100% in children and adults alike with a hyperesponse of 79% and 71% respectively. The vaccine Heberbiovac HB shows high immunogenicity with very short latency, intensity higher than other plasmatic and recombinant vaccines and great durability. This vaccine had an booster effect on those individuals showing hyperesponse to other anti-HB vaccines because 15 days after the innoculation, 75% of vaccinated persons had protective antibodies in their sera
Keywords : VACCINES, SYNTHETIC [immunology]; VACCINES SYNTHETIC [administration and doses]; HEPATITIS B VACCINES [immunology]; HEPATITIS B VACCINES [administration and doses]; IMMUNIZATION SCHEDULE.